<DOC>
	<DOCNO>NCT02912247</DOCNO>
	<brief_summary>This clinical study phase 1 study carry establish pharmacokinetic equivalence equal safety human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection Adalimumab use single subcutaneous injection healthy volunteer .</brief_summary>
	<brief_title>Comparative Clinical Trial Evaluate Bioequivalency Safety Monoclonal Antibody Injection Adalimumab Chinese Healthy Volunteers</brief_title>
	<detailed_description>This comparative , open , randomized clinical study . The purpose study demonstrate human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection equivalent adalimumab term pharmacokinetics safety single subcutaneous injection Chinese healthy volunteers.The study enroll 180 healthy volunteer , randomize 2 group .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Male , age 18 55 ; 2 . Body weight≥50kg body mass index ( BMI ) within range 19 28 kg/m2 ; 3 . To fully understand purpose study , understand pharmacological action study drug possible adverse reaction ; participant voluntary sign inform consent accord Declaration Helsinki . 1 . History adalimumab treatment ; 2 . History relevant allergy/hypersensitivity ( include allergy study drug ingredient ) ; 3 . Participation another interventional trial within 3 month prior administration study drug ; 4 . Blood donation ( 200 mL within 12 week prior administration study drug ) ; 5 . Use drug ( include traditional Chinese medicine ) within 2 week least 5 halflives ( whichever longer ) prior administration ; 6 . History cluster differentiation 4 antagonist tumor necrosis factor alpha antagonist use , use tumor necrosis factor antagonist ( thalidomide ) 3 month prior administration ; 7 . Abnormal significant clinically chest radiograph , ECG , laboratory examination screen Baseline , judge investigator ; 8 . History opportunistic infection ( ) ( : herpes zoster , mycoplasma , Pneumocystis carinii , histoplasma , Aspergillus , mycobacterium ) within 6 month prior screen ; 9 . Known recurrent chronic infectious disease ( ) history , include limited : chronic kidney infect , chronic chest infection ( bronchiectasis ) , nasosinusitis , recurrent urinary tract infection , open , drainage infect wound skin ; 10 . Tuberculosis ( TB ) history , suspect clinically TB ( include limit : pulmonary tuberculosis , lymphoid tuberculosis , tuberculous pleurisy ) , positive Tuberculosis spot test ; 11 . Positive serology human immunodeficiency virus ( HIV ) antibody ; 12 . Positive serology hepatitis C virus antibody ; 13 . Active chronic hepatitis B virus infection , positive hepatitis B virus surface antigen ; 14 . History organ transplant ( except corneal transplantation≥3 month prior Screening ) ; 15 . Known immunodeficiency history ; 16 . Use live vaccine within 3 month prior administration ; 17 . Alcohol drug abuse within 12 month prior Screening ; unwilling/inability refrain alcohol 72 hour prior administration trial period ; 18 . Unwilling use adequate contraception ( condom ) study period ; 19 . Evidence suggest presence clinically significant hepatic , renal , gastrointestinal , cardiovascular , endocrine , respiratory , hematologic , neurologic abnormality ; 20 . Mentally impaired ; 21 . Disabilities , bed rest , wheelchair dependent , lack activity daily life ; 22 . Subjects unsuited study reason , judge investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>tumor necrosis factor-a blocker</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>safety</keyword>
</DOC>